Vincent Trebosc was born in 1989 in Saint-Affrique, France. After getting a technical degree in Biology at the University Paul Sabatier, he joined in 2010 the National Institute of Applied Science (INSA) of Toulouse. In 2013, he obtained his Engineer’s degree in Biochemistry with a specialisation in Systems and Synthetic Biology. He performed his master thesis in the PHYGE research group at the Laboratoire d’Ingénierie des Systèmes Biologiques et des Procédés. His work focused on the development of synthetic metabolic pathways for pentose assimilation and production of added-value compounds in Escherichia coli.
In January 2014, Vincent joined the Marie Sklodowska Curie ITN Translocation project as PhD student with a joint program of BioVersys AG, Switzerland, and the University of Basel. BioVersys is a bio-pharmaceutical start-up company developing drugs that allow to switch-off antibiotic resistances in bacterial drug resistant pathogens. Vincent’s work at BioVersys focuses on the characterization of resistance mechanisms in Gram-negative pathogens to identify drug targets and to develop small molecule inhibitors of antibiotic resistance. He is particularly interested in developing novel methods that allow the drug target validation in clinically derived multidrug resistant pathogens.
- Trebosc, V. et al. A Novel Genome-Editing Platform for Drug-Resistant Acinetobacter baumannii Reveals an AdeR-Unrelated Tigecycline Resistance Mechanism. Antimicrob. Agents Chemother. 60, 7263–7271 (2016).
- Trebosc, V. et al. Reversion of Antibiotic Resistance in Mycobacterium tubercolosis by spiroisoxazoline SMARt-420. Science 2017. Mar 17;355(6330): 1206-1211.